Paradigm Capital Management Inc. NY Buys Shares of 2,536,699 Accendra Health, Inc. $ACH

Paradigm Capital Management Inc. NY bought a new stake in shares of Accendra Health, Inc. (NYSE:ACH) during the second quarter, HoldingsChannel.com reports. The fund bought 2,536,699 shares of the company’s stock, valued at approximately $8,676,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of ACH. Walleye Capital LLC purchased a new stake in Accendra Health in the first quarter worth $27,000. Hsbc Holdings PLC purchased a new stake in shares of Accendra Health during the first quarter valued at $34,000. Abel Hall LLC purchased a new stake in shares of Accendra Health during the first quarter valued at $44,000. Keybank National Association OH bought a new position in shares of Accendra Health in the first quarter worth about $46,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Accendra Health in the first quarter worth about $50,000.

Accendra Health Stock Down 5.4%

NYSE ACH opened at $1.14 on Tuesday. Accendra Health, Inc. has a one year low of $0.93 and a one year high of $5.69. The stock has a market cap of $87.28 million, a P/E ratio of -0.29 and a beta of 1.58. The firm’s 50-day simple moving average is $2.83.

Accendra Health (NYSE:ACH) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.06). Accendra Health had a negative return on equity of 4.02% and a negative net margin of 11.41%.The business had revenue of $613.23 million during the quarter. As a group, equities research analysts expect that Accendra Health, Inc. will post -0.03 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Robert W. Baird set a $1.50 price target on shares of Accendra Health and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. UBS Group dropped their target price on shares of Accendra Health from $4.50 to $1.50 and set a “neutral” rating on the stock in a research note on Thursday, August 13th. Citigroup lowered shares of Accendra Health from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $4.50 to $1.50 in a research report on Monday, August 10th. Finally, Weiss Ratings downgraded shares of Accendra Health from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 6th. Four equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $1.50.

Accendra Health Profile

Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services.